These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
647 related articles for article (PubMed ID: 17559369)
1. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. Chang FY; Lu CL; Chen CY; Luo JC J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369 [TBL] [Abstract][Full Text] [Related]
2. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
3. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790 [TBL] [Abstract][Full Text] [Related]
4. Octatropine methyl bromide and diazepam combination (Valpinax) in patients with irritable bowel syndrome: a multicentre, randomized, placebo-controlled trial. Pace F; Maurano A; Ciacci C; Savarino V; Attili A; Iaquinto G; Magni E; Porro GB Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):155-62. PubMed ID: 20391952 [TBL] [Abstract][Full Text] [Related]
5. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Leung WK; Wu JC; Liang SM; Chan LS; Chan FK; Xie H; Fung SS; Hui AJ; Wong VW; Che CT; Sung JJ Am J Gastroenterol; 2006 Jul; 101(7):1574-80. PubMed ID: 16863563 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028 [TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028 [TBL] [Abstract][Full Text] [Related]
8. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Mangel AW; Bornstein JD; Hamm LR; Buda J; Wang J; Irish W; Urso D Aliment Pharmacol Ther; 2008 Jul; 28(2):239-49. PubMed ID: 18466359 [TBL] [Abstract][Full Text] [Related]
9. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. Wittmann T; Paradowski L; Ducrotté P; Bueno L; Andro Delestrain MC Aliment Pharmacol Ther; 2010 Mar; 31(6):615-24. PubMed ID: 20003095 [TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Tack JF; Miner PB; Fischer L; Harris MS Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Rahimi R; Nikfar S; Abdollahi M Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935 [TBL] [Abstract][Full Text] [Related]
12. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Leventer SM; Raudibaugh K; Frissora CL; Kassem N; Keogh JC; Phillips J; Mangel AW Aliment Pharmacol Ther; 2008 Jan; 27(2):197-206. PubMed ID: 17973974 [TBL] [Abstract][Full Text] [Related]
13. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433 [TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002 [TBL] [Abstract][Full Text] [Related]
15. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Vahedi H; Merat S; Momtahen S; Kazzazi AS; Ghaffari N; Olfati G; Malekzadeh R Aliment Pharmacol Ther; 2008 Apr; 27(8):678-84. PubMed ID: 18248658 [TBL] [Abstract][Full Text] [Related]
16. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426 [TBL] [Abstract][Full Text] [Related]
17. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome. Dumitraşcu DL; Stănculete M Rom J Intern Med; 2006; 44(3):273-80. PubMed ID: 18386606 [TBL] [Abstract][Full Text] [Related]
18. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437 [TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. Saito YA; Rey E; Almazar-Elder AE; Harmsen WS; Zinsmeister AR; Locke GR; Talley NJ Am J Gastroenterol; 2010 Jan; 105(1):170-7. PubMed ID: 19809408 [TBL] [Abstract][Full Text] [Related]
20. Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo. Ziegenhagen DJ; Kruis W J Gastroenterol Hepatol; 2004 Jul; 19(7):744-9. PubMed ID: 15209619 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]